Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
Are you looking for a stable dividend payer or a high-growth medical innovator? Choosing between Amgen (NASDAQ:AMGN) and Eli Lilly & Co. (NYSE:LLY) depends on your specific goals for 2026.
Amgen operates as a mature biotechnology leader focused on cost-efficient manufacturing and specialty drugs. Eli Lilly & Co. has recently transformed into a growth powerhouse through its breakthrough obesity and diabetes treatments. Both companies command significant market share, but their financial profiles and valuation multiples suggest very different paths for potential investors.
Amgen discovers and manufactures innovative medicines for serious illnesses, focusing on oncology, inflammation, and rare diseases. It distributes its products primarily through large wholesalers like McKesson Corp. (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). Customer concentration like this adds a layer of risk to the business, as these three entities account for a significant portion of its total revenue.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.